

CLEAN VERSION OF REWRITTEN, ADDED, AND/OR CANCELLED
CLAIMS PURSUANT TO 37 C.F.R. §1.121 (c)(1)(i)

Replace Claims 1, 2, 13, 19, 55, 57, 65-67, 70-72, 75, 80, 82, 84, 86, 90, 92, 94, 96, 106, 108, 110, 112, 114, 116, 117, and 119, with the following claims of corresponding number and add the following Claims 121-123.

C1 1. (Once Amended) A method of reducing or inhibiting angiogenesis in a tissue, comprising contacting $\alpha 5 \beta 1$ integrin in the tissue with an $\alpha 5 \beta 1$ antagonist that interferes with specific binding of the $\alpha 5 \beta 1$ integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue.

2. (Once Amended) The method of claim 1, wherein the antagonist does not substantially interfere with the specific binding of a ligand to an integrin other than $\alpha 5 \beta 1$ integrin to its ligand.

C2 13. (Once Amended) The method of claim 1, wherein the antagonist comprises a peptide.

C3 19. (Once Amended) The method of claim 1, wherein the antagonist is linked to a cytotoxin.

C4 55. (Once Amended) A method of reducing or inhibiting angiogenesis in a tissue in an individual, comprising administering to the individual an $\alpha 5 \beta 1$ antagonist that interferes with the specific binding of $\alpha 5 \beta 1$ integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue in the individual.

C5 57. (Once Amended) A method of reducing the severity of a pathological condition associated with angiogenesis in an individual, comprising administering to the individual an $\alpha 5 \beta 1$ antagonist that interferes with specific binding of $\alpha 5 \beta 1$ integrin to a

C5
ligand in a tissue associated with the pathological condition, thereby reducing or inhibiting angiogenesis in the tissue, and reducing the severity of the pathological condition.

65. (Once Amended) The method of claim 57, wherein the antagonist is administered intravenously.

C6
66. (Once Amended) The method of claim 57, wherein the antagonist is administered orally.

67. (Once Amended) The method of claim 58, wherein the antagonist is administered into a neoplasm.

70. (Once Amended) The method of claim 68, wherein the antagonist is administered in the form of eye drops.

C7
71. (Once Amended) The method of claim 68, wherein the antagonist is administered intravenously.

72. (Once Amended) The method of claim 68, wherein the antagonist is administered orally.

C8
75. (Once Amended) The method of claim 57, wherein the antagonist is administered at a dose of 0.0001 to 100 mg/kg body weight.

C9
80. (Once Amended) The method of Claim 1, wherein the binding of said antagonist to said $\alpha 5 \beta 1$ integrin is at least two-fold greater than the binding of said antagonist to an integrin other than $\alpha 5 \beta 1$ integrin.

C10
82. (Once Amended) The method of Claim 1, wherein the binding of said antagonist to said $\alpha 5 \beta 1$ integrin is at least five-fold greater than the binding of said antagonist to an integrin other than $\alpha 5 \beta 1$ integrin.

84. (Once Amended) The method of Claim 1, wherein the binding of said antagonist to said $\alpha 5 \beta 1$ integrin is at least ten-fold greater than the binding of said antagonist to an integrin other than $\alpha 5 \beta 1$ integrin.

86. (Once Amended) The method of Claim 1, wherein said antagonist does not interfere with the specific binding of a ligand to an integrin other than $\alpha 5 \beta 1$ integrin.

90. (Once Amended) The method of Claim 55, wherein the binding of said antagonist to said $\alpha 5 \beta 1$ integrin is at least two-fold greater than the binding of said antagonist to an integrin other than $\alpha 5 \beta 1$ integrin.

92. (Once Amended) The method of Claim 55, wherein the binding of said antagonist to said $\alpha 5 \beta 1$ integrin is at least five-fold greater than the binding of said antagonist to an integrin other than $\alpha 5 \beta 1$ integrin.

94. (Once Amended) The method of Claim 55, wherein the binding of said antagonist to said $\alpha 5 \beta 1$ integrin is at least ten-fold greater than the binding of said antagonist to an integrin other than $\alpha 5 \beta 1$ integrin.

96. (Once Amended) The method of Claim 55, wherein said antagonist does not interfere with the specific binding of a ligand to an integrin other than $\alpha 5 \beta 1$ integrin.

106. (Once Amended) The method of Claim 55, wherein said antagonist comprises a peptide.

108. (Once Amended) The method of Claim 55, wherein said antagonist is linked to a cytotoxin.

110. (Once Amended) The method of Claim 57, wherein the binding of said antagonist to said $\alpha 5 \beta 1$ integrin is at least two-fold greater than the binding of said antagonist to an integrin other than $\alpha 5 \beta 1$ integrin.

C20
112. (Once Amended) The method of Claim 57, wherein the binding of said antagonist to said $\alpha 5 \beta 1$ integrin is at least five-fold greater than the binding of said antagonist to an integrin other than $\alpha 5 \beta 1$ integrin.

C21
114. (Once Amended) The method of Claim 57, wherein the binding of said antagonist to said $\alpha 5 \beta 1$ integrin is at least ten-fold greater than the binding of said antagonist to an integrin other than $\alpha 5 \beta 1$ integrin.

116. (Once Amended) The method of Claim 57, wherein said antagonist does not interfere with the specific binding of a ligand to an integrin other than $\alpha 5 \beta 1$ integrin.

C22
117. (Once Amended) The method of Claim 57, wherein said antagonist comprises a peptide.

C23
119. (Once Amended) The method of Claim 57, wherein said antagonist is linked to a cytotoxin.

D1
121. (New) A method of reducing or inhibiting angiogenesis in a tissue, comprising contacting $\alpha 5 \beta 1$ integrin in the tissue with an $\alpha 5 \beta 1$ antagonist that induces endothelial cell apoptosis and interferes with specific binding of the $\alpha 5 \beta 1$ integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue.

C24
122. (New) A method of reducing or inhibiting angiogenesis in a tissue in an individual, comprising administering to the individual an $\alpha 5 \beta 1$ antagonist that induces endothelial cell apoptosis and interferes with the specific binding of $\alpha 5 \beta 1$ integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue in the individual.

123. (New) A method of reducing the severity of a pathological condition associated with angiogenesis in an individual, comprising administering to the individual an $\alpha 5 \beta 1$ antagonist that induces endothelial cell apoptosis and interferes with specific binding of

cy $\alpha 5 \beta 1$ integrin to a ligand in a tissue associated with the pathological condition, thereby reducing or inhibiting angiogenesis in the tissue, and reducing the severity of the pathological condition.